BP
NVAX icon

Banyan Partners’s Novavax NVAX Stock Holding History

Banyan Partners’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$63K Hold
750
– – 0.01% 385
2014
Q2 		$69K Buy
750
+250
+50% +$22K 0.01% 376
2014
Q1 		$45K Hold
500
– – ﹤0.01% 378
2013
Q4 		$51K Buy
+500
New +$35.3K ﹤0.01% 396

Other funds holding NVAX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Banyan Partners's NVAX Position: Q3 2014 in Review

Banyan Partners held its Novavax (NVAX) position steady in Q3 2014 at 750 shares worth $63K. The position accounts for 0.01% of the portfolio, ranked #385.

Banyan Partners first reported a position in NVAX in Q4 2013 and has held it in 4 quarters since. The position peaked at $69K in Q2 2014. 143 funds tracked by Wall St. Rank hold NVAX as of Q3 2014.

  • Banyan Partners held 750 shares of Novavax worth $63K as of Q3 2014.
  • Banyan Partners left its Novavax share count unchanged in Q3 2014.
  • Novavax made up 0.01% of Banyan Partners's portfolio in Q3 2014, its #385 holding.
  • Banyan Partners first reported a position in Novavax in Q4 2013 and has held it in 4 quarters since.
  • Banyan Partners's Novavax position peaked at $69K in Q2 2014.
  • 143 funds tracked by Wall St. Rank held Novavax as of Q3 2014.

Based on Banyan Partners's 13F filing for Q3 2014, filed 14 Nov 2014.